Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als crawled time : 13:00 save search
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CLNN 4 | $0.337 0.57% 0.68% 300K
|
|
| O: 2.33%
H: 1.69%
C: -6.56%
au8 als treatment
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
Published: 2023-12-05 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: -30.2%
H: 20.19%
C: 8.65%
als trial phase 2
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
KTTA | $6.9501 -1.97% -1.19% 910
|
|
| O: -3.9%
H: 4.05%
C: 4.05%
pas-003 antibody als treatment therapeutics
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
Published: 2023-10-04 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 12.07%
H: 5.24%
C: -17.83%
primec als
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
Published: 2023-10-02 (Crawled : 13:00) - prnewswire.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 18.35%
H: 2.48%
C: -16.71%
company beyond als offering results
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Published: 2023-09-19 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 4.56%
H: 1.15%
C: -3.78%
drug primec israel als granted
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
Published: 2023-09-14 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 3.77%
H: 0.0%
C: -2.63%
als
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
Published: 2023-09-07 (Crawled : 13:00) - prnewswire.com
SNPX | $4.56 -0.22% 0.65% 14K
|
Professional, Scientific, and T...
|
| O: 9.31%
H: 5.47%
C: -19.7%
pre-clinical als treatment results study
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
Published: 2023-07-11 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 1.42%
H: 2.8%
C: -2.8%
als network biomarkers
Genau warum ist zu diesem Zeitraum Anders als anderen Personen für über das Internet Daten?
Published: 2023-07-04 (Crawled : 13:00) - nxtenergy.com
NSFDF | $0.1298 7.1% 317.8% 0
|
Industrial Services
| Email alert
Add to watchlist
internet als
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
Published: 2023-06-01 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: -2.56%
H: 5.26%
C: 3.29%
business als expected topline trial financial results
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.2M
|
|
| O: -4.63%
H: 8.23%
C: 1.52%
amx0035 als review update treatment ongoing pharmaceuticals
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
Published: 2023-05-15 (Crawled : 13:00) - prnewswire.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 3.34%
H: 1.86%
C: -3.23%
als trial
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
Published: 2023-04-17 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: -4.29%
H: 5.13%
C: 2.56%
ceo als trial
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Published: 2023-03-23 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.34 -1.47% -2.26% 130K
|
|
| O: 0.0%
H: 4.85%
C: 0.61%
conference disease als alzheimer's therapy
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
QURE | $4.56 -4.0% -3.94% 640K
|
Health Technology
|
| O: 1.21%
H: 2.92%
C: 1.72%
apb-102 global als agreement therapy
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
Published: 2022-12-05 (Crawled : 13:00) - prnewswire.com
IONS | $42.45 1.46% 1.45% 730K
|
Health Technology
|
| O: -0.32%
H: 0.6%
C: -3.01%
genetic als application authorization
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
Published: 2022-12-05 (Crawled : 13:00) - globenewswire.com
ATHA | $2.01 -1.47% -0.99% 79K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -9.26%
ath-1105 pharma preclinical als symposium potential international
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium
Published: 2022-11-28 (Crawled : 13:00) - biospace.com/
ATHA | $2.01 -1.47% -0.99% 79K
|
Health Technology
|
| O: -0.67%
H: 0.67%
C: -4.38%
ath-1105 pharma preclinical als symposium potential international
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.